Welcome & Housekeeping: Kumar Shah opened the meeting and reminded everyone to sign the rosters and announced a quorum. Jennifer Strohecker introduced new clinical pharmacist Ngan Huynh in the Bureau of Coverage and Reimbursement Policy.

Review and Approval of Choose an item Minutes: Eric Cannon made a motion to Approve the minutes from August and noted the minutes were lengthy. Jennifer Brinton seconded the motion. All in favor, motion passed.

Prior Authorization Updates:
- Entresto: Jennifer Strohecker discussed Entresto utilization data, carry over from August DUR meeting. Medicaid suggested to remove Entresto prior
authorization due to low denial rate. In the last year, there were 38 claims for Entresto. 25 Entresto requests were approved and 4 were denied, possibly due to missing information. Jennifer Strohecker asked if the board recommends to remove PA or to keep it in place. Eric motioned to remove Entresto PA, Neal Catalano seconded the motion. Unanimous vote.

b. **Antiemetic Prior Authorization form:** Mohit Bhakta introduced changes to the Antiemetic Prior Authorization form. “Medical Buy and Bill” and “Pharmacy Point of Sale” check box options were added to differentiate between a medical and pharmacy billing prior authorization request and a note stating Civanti (aprepitant) must be used in combination with other antiemetic agent(s). Michelle Hoffman suggested the word “request” in the note box be removed. Jennifer Brinton suggested the title of the PA form clarify what types of antiemetics require PA, since diagnoses listed on form are oncology related. With changes, Neal Catalano motioned to approve PA form. Michelle Hoffman seconded the motion. Unanimous vote.

c. **Butalbital Containing Products:** Jennifer Strohecker discussed butalbital containing prior authorization. Medicaid suggested prior authorization be removed and asked board for recommendation. Jennifer Brinton suggested an age limit. Jennifer Strohecker clarified that butalbital products will be available for those 18 years and older. Susan Siegfried mentioned the American Academy of Neurology discourages the use of butalbital. There was a lengthy discussion regarding efficacy and benefit of butalbital. Sharon Weinstein recommended a quantity limit of 12 tablets per month. Medicaid will look into claims data and review for appropriate quantity limit and bring back to board. Jennifer Brinton motioned to remove PA and add age edit for 18 years and older. Katherine Smith seconded motion. Unanimous vote.

4. **Antipsychotics in Children and Adolescents:**

   a. **Information:** Valerie Gonzales with University of Utah College of Pharmacy presented antipsychotic use in children. Antipsychotics use in children is highest among those in foster care within Medicaid. Valerie went over current recommendations for antipsychotics use in children, first line treatment before use of an antipsychotic, side effects of antipsychotics, and contraindications of antipsychotic use in children. Jennifer Strohecker presented current data of antipsychotic use in children and what Medicaid will implement to comply with SUPPORT Act which will be effective October 1st. Medicaid suggested pharmacy prior authorization on antipsychotics used in children who are younger than 6 years of age, receiving more than 1 antipsychotic, and/or are being prescribed high doses of antipsychotics. There was a lengthy discussion regarding barriers of care because of safety concerns and ease of access in rural areas. Some of these children are sometimes violent and provider must be remote to treat. Also, those in rural areas are receiving antipsychotics by pediatricians or primary care provider because psychiatrists and specialists are out of reach because of distance. Susan suggested to consider removing PA for children receiving more than one antipsychotic and to follow FDA recommendations and
Texas Standard dosing requirements and threshold. She suggested to allow more than one antipsychotic for 30 days, then require diagnosis code for subsequent fills. Medicaid system does not have the ability to place such an edit.

b. **Public Comment:** Michael Nelsen with Sunovion excused Dr. Clark, who was scheduled to comment. Michael respectfully gave time back to board for further discussion. Roy Lindfield with Sunovion commented that Utah Medicaid criteria is similar to other States and agreed with board regarding care barriers.

c. **Board Action:** Eric motioned to place prior authorization on antipsychotics used in children who are younger than 6 years of age, receiving more than 1 antipsychotic for all children under 18 years of age, and/or are being prescribed high doses of antipsychotics according to Texas Standard dosing. A diagnosis will be required at point of sale. Susan Siegfreid seconded the motion.

5. **Public Meeting Adjourned:** Kumar excused board. DUR adjourned.

6. **The next meeting scheduled for Thursday, October 10, 2019.**